Sequitur, Inc.

The word "Sequitur" comes from the same Latin root as "sequence." Recently, the decoding or "sequencing" of at least a portion of most human genes has been completed. The challenge now is to analyze the function of these sequences and to create new therapies based on these sequences.

Sequitur, Inc. was founded in 1996 to develop innovative sequence-based compounds for functional genomics research, diagnostic and therapeutic applications. Sequitur's proprietary antisense technology can be employed to determine gene function and validate small molecule targets by specifically inhibiting gene expression. We also offer a line of products and services relating to gene expression and gene detection. Research is performed in our recently renovated state-of-the-art GLP cellular and molecular biology laboratory space in Natick, Massachusetts. Sequitur's scientific advisory board includes leaders in the fields of oligonucleotide and gene therapy research.

Sequitur provides services in the following interrelated areas:

ANTISENSE FUNCTIONAL GENOMICS SUBSCRIPTION PROGRAM
Based upon a yearly licensing fee, a corporate client obtains non-exclusive research use of Sequitur's current and newly developed functional genomics technology. Sequitur has one issued patent and five patents pending in the field of oligonucleotide technology. Research agreements are also available for Sequitur to experimentally determine optimal antisense sites within target genes. Eight of the top 20 pharmaceutical companies world-wide are currently using Sequitur's antisense program. Clients include:

• Pharmacia & Upjohn
• Chiron
• Genome Therapeutics
• Inex Pharmaceuticals
• Mitotix
• Monsanto-Searle
• Genetics Institute
• Incyte
• Amgen
• Wyeth-Ayerst
• Bristol-Myers Squibb

COLLABORATIVE RESEARCH
We have collaborated with a major synthetic DNA supplier to produce our first product and we continually test new compounds developed externally and internally. We have performed collaborative research projects with Inex Pharmaceuticals, Genome Therapeutics, Affymetrix and others.

SPECIALTY RESEARCH PRODUCTS
Sequitur provides a wide selection of custom ordered modified DNA for research and diagnostic applications. We offer proprietary improved antisense oligonucleotides and delivery vehicles through our Functional Genomics Antisense Program.

Currently, Sequitur is funded internally and through collaborative agreements. In the future Sequitur may seek equity financing. Please contact us with any questions about Sequitur or synthetic DNA applications